$28.61
8.33% day before yesterday
Nasdaq, Sep 12, 10:09 pm CET
ISIN
US8902604094
Symbol
TNXP

Tonix Pharmaceuticals Holding Corp. Stock price

$28.61
-31.15 52.13% 1M
+15.20 113.35% 6M
-4.37 13.25% YTD
+12.64 79.15% 1Y
-19,311.39 99.85% 3Y
-492,707.39 99.99% 5Y
-4,703,999,971.39 100.00% 10Y
-1,279,971.39 100.00% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-2.60 8.33%
ISIN
US8902604094
Symbol
TNXP
Industry

Key metrics

Basic
Market capitalization
$250.8m
Enterprise Value
$125.5m
Net debt
positive
Cash
$125.3m
Shares outstanding
7.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
25.5 | 20.5
EV/Sales
12.8 | 10.3
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
85.7%
Return on Equity
-93.2%
ROCE
-50.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.8m | $12.2m
EBITDA
$-82.5m | -
EBIT
$-84.5m | $-108.2m
Net Income
$-81.4m | $-100.3m
Free Cash Flow
$-65.4m
Growth (TTM | estimate)
Revenue
-21.1% | 21.2%
EBITDA
8.6% | -
EBIT
11.3% | -39.2%
Net Income
45.4% | 22.9%
Free Cash Flow
13.5%
Margin (TTM | estimate)
Gross
29.3%
EBITDA
-839.1% | -
EBIT
-859.3%
Net
-828.2% | -819.6%
Free Cash Flow
-665.1%
More
EPS
$-11.1
FCF per Share
$-8.7
Short interest
13.4%
Employees
81
Rev per Employee
$120.0k
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

Buy
88%
Hold
13%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
9.83 9.83
21% 21%
100%
- Direct Costs 6.95 6.95
29% 29%
71%
2.88 2.88
7% 7%
29%
- Selling and Administrative Expenses 50 50
34% 34%
505%
- Research and Development Expense 36 36
41% 41%
363%
-82 -82
9% 9%
-839%
- Depreciation and Amortization 1.98 1.98
60% 60%
20%
EBIT (Operating Income) EBIT -84 -84
11% 11%
-859%
Net Profit -81 -81
45% 45%
-828%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Neutral
GlobeNewsWire
6 days ago
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo Tonmya showed consistent improvements across core fibromyalgia symptoms, including widespread pain, sleep disturbance and fatigue T...
Neutral
GlobeNewsWire
17 days ago
CHATHAM, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D.
Positive
Seeking Alpha
26 days ago
The Tonix Pharmaceuticals Holding Corp. stock price has pulled back so much, and they hold a clear campaign runway for Tonmya into 2026. Despite approval, TNXP shares dropped due to concerns over valuation, potential dilution, and uncertainty around commercialization and pricing. Tonmya's novel formulation and high unmet need could drive strong adoption, with revenue potential of $219M–$365M an...
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 81
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today